Glycemic optimization

Glycemic optimization has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Mar 6, 2026: “Impact of glycemic optimization on myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes: a longitudinal study”.

Intervention

1 paper studies it4 findingsUpdated

See all 1 papers on glycemic optimization

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Participants (mean age 54.8 ± 9 years, 72.3% male) achieved significant reductions in HbA1c levels, body mass index (BMI) and waist circumference (WC).”
Impact of glycemic optimization on myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes: a longitudinal studyCardiovascular diabetology2026doi:10.1186/s12933-026-03105-3

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funders: Agència de Gestió d'Ajuts Universitaris i de Recerca and others
  • Human trial1

Studies in people

1 study gave glycemic optimization to people and measured what changed.

What changedDesignPeopleSource

down: Decreases HbA1c

no change: Has no effect on myocardial triglyceride contentp = 0.23

up: Increases left ventricular ejection fraction59.0% [54.8-61.5] vs. 63.1% [56.9-66.3], p = 0.01

Trial12 months20 peopleBothmean age 54.8 ± 9 yearsMidlife adults; newly diagnosed type 2 diabetesCardiovascular diabetology, Mar 6, 2026

What did studies of glycemic optimization find?

4

Studies of glycemic optimization measured 4 outcomes, among them Left ventricular end-systolic volume, left ventricular ejection fraction and myocardial triglyceride content.

Left ventricular end-systolic volume

downin humans1

1 study
  1. Glycemic optimization decreases Left ventricular end-systolic volume in humans (newly diagnosed type 2 diabetes) (29.9 mL/m2 [26.4-35.1] vs. 27.3 mL/m2 [22.5-31.7]; p = 0.007).

    “decreases in ventricular volumes: (LV) end-systolic volume (29.9 mL/m2 [26.4-35.1] vs. 27.3 mL/m2 [22.5-31.7]; p = 0.007)”

    Human trialnewly diagnosed type 2 diabetes12 monthsn = 20

    Impact of glycemic optimization on myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes: a longitudinal study

    Cardiovascular diabetology

More on Left ventricular end-systolic volume

Left ventricular ejection fraction

upin humans1

1 study
  1. Glycemic optimization increases left ventricular ejection fraction in humans (newly diagnosed type 2 diabetes) (59.0% [54.8-61.5] vs. 63.1% [56.9-66.3], p = 0.01).

    “CMR evaluation revealed increases in left ventricle (LV) ejection fraction (59.0% [54.8-61.5] vs. 63.1% [56.9-66.3], p = 0.01)”

    Human trialnewly diagnosed type 2 diabetes12 monthsn = 20

    Impact of glycemic optimization on myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes: a longitudinal study

    Cardiovascular diabetology

More on Left ventricular ejection fraction

Myocardial triglyceride content

no changein humans1

1 study
  1. Glycemic optimization showed no clear effect on myocardial triglyceride content in humans (newly diagnosed type 2 diabetes) (p = 0.23).

    “No significant changes in MTGC were found at follow-up (p = 0.23).”

    Human trialnewly diagnosed type 2 diabetes12 monthsn = 20

    Impact of glycemic optimization on myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes: a longitudinal study

    Cardiovascular diabetology

More on Myocardial triglyceride content

HbA1c

downin humans1

1 study
  1. Glycemic optimization decreases HbA1c in humans (newly diagnosed type 2 diabetes).

    “Participants (mean age 54.8 ± 9 years, 72.3% male) achieved significant reductions in HbA1c levels, body mass index (BMI) and waist circumference (WC).”

    Human trialnewly diagnosed type 2 diabetes12 monthsn = 20

    Impact of glycemic optimization on myocardial steatosis and cardiac remodeling in patients with newly diagnosed type 2 diabetes: a longitudinal study

    Cardiovascular diabetology

More on HbA1c

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months